Angiotensin II isn't a research-chemical peptide or an experimental obesity candidate — it's a short peptide hormone the body already makes, and a synthetic version of it has been an FDA-approved intensive-care drug since 2017. It's a useful example of how differently peptide drugs can be used depending on the medical context.
What It Is and How It Works
Angiotensin II is a small peptide, naturally produced as part of the renin-angiotensin-aldosterone system, the body's primary hormonal pathway for regulating blood pressure. It works by binding receptors on blood vessel walls and causing them to constrict, which raises blood pressure. The FDA-approved drug Giapreza is a synthetic formulation of this same peptide, given as a continuous intravenous infusion in a hospital intensive care setting.
What It's Approved For
Giapreza is approved to increase blood pressure in adults with septic shock or other types of distributive shock — life-threatening conditions in which blood vessels become too relaxed and blood pressure drops dangerously low, often as a complication of severe infection. It is not a first-line treatment. It's used alongside other vasopressor drugs, such as norepinephrine, when those standard options aren't adequately raising blood pressure on their own.
The Evidence Behind Approval
Giapreza's approval was based on the ATHOS-3 trial, a randomized, placebo-controlled study in adults with catecholamine-resistant distributive shock — meaning their blood pressure wasn't responding adequately to standard vasopressors alone. This is direct human clinical-trial evidence, not an extrapolation from animal studies, which sets it apart from how most unregulated research-chemical peptides are marketed. The trial found that significantly more patients receiving angiotensin II achieved target blood pressure within three hours compared with those receiving placebo on top of their existing treatment. A later analysis of the same trial also reported a survival association in the sickest patients, those with the highest illness-severity scores, though overall survival was not the trial's primary endpoint, and that finding should be read as supportive rather than definitive on its own.
Safety Considerations
Because angiotensin II is a potent vasoconstrictor, its main safety concern is an increased risk of blood clots, including both venous and arterial thrombosis, observed in clinical trials. For that reason, patients receiving it are typically also given blood-clot prevention measures unless a specific reason rules that out. Close blood-pressure and perfusion monitoring, along with thrombosis monitoring, is standard practice during its use.
Not a Self-Administered Drug
Unlike GLP-1 drugs or growth-hormone peptides that patients self-inject at home, angiotensin II is administered only by continuous IV infusion under direct ICU supervision, with dosing titrated minute to minute based on blood-pressure response. There's no outpatient or self-administered version, and none is being developed for that purpose. The usual "talk to your doctor before starting a peptide" framing doesn't really apply here the way it does for outpatient drugs — this is a decision made by the treating critical-care team in real time, not a choice a patient makes independently.
How It Relates to Other Peptide Drugs on the Market
Angiotensin II sits at the opposite end of the pharmacology spectrum from drugs like ACE inhibitors or angiotensin-receptor blockers, which are common blood-pressure medications that block this same hormonal pathway to lower blood pressure in chronic hypertension. Giapreza instead supplements the pathway to raise blood pressure acutely. Researchers have continued studying angiotensin II for other potential uses, including certain cases of liver-related low blood pressure (hepatorenal syndrome), but those remain investigational and are not current FDA-approved indications.